CCTL019B2003I: Managed Access Program (MAP) to provide access to CTL019, for acute lymphoblastic leukemia (ALL) in diffuse large b-cell lymphoma (DLBCL) patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release | WVU Cancer Institute Clinical Research Unit

Managed Access Program (MAP) to provide access to CTL019, for acute lymphoblastic leukemia (ALL) in diffuse large b-cell lymphoma (DLBCL) patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release

Principal Investigator

Veltri, Lauren

Phase

NA

Age Group

Adult

Applicable Disease Sites

Leukemia

Lymphoma

Participating Institution

Mary Babb Randolph Cancer Center

Contact